4 Consumer Discretionary Stocks to Grab as Inflation Continues to Ease

CPI rose 0.2% month-over-month in January vs. 0.3% consensus and 2.4% year-over-year (down 0.3ppt from December); Core CPI +0.3% MoM and 2.5% YoY (lowest since April 2021). The softer inflation print boosts odds of Fed rate cuts after last year’s cumulative 75bps of easing and the January pause, supporting risk assets. Zacks recommends four consumer-discretionary buys: Accel Entertainment (ACEL, Zacks #2; FY earnings growth est +15%, consensus est +9.5% revision 60d), Crocs (CROX, Zacks #2; +7% growth, +6.4% revision), Alto Ingredients (ALTO, Zacks #1; >100% growth, +18.8% revision) and Dolby Laboratories (DLB, Zacks #2; +1.7% growth, +2.6% revision).

Analysis

Easing inflation and a market that is pricing earlier rate relief re-orders winners in two obvious and one less obvious way: (1) lower real rates lifts present values and multiple expansion for long-duration royalty/licensing models, (2) cheaper capital re-accelerates discretionary spending and private M&A in fragmented service industries, and (3) it raises the risk that a transient slowdown in goods inflation masks sticky services/income pressures that would re-price risk rapidly. Expect the first-order multiple rerating to show up within 2–6 months while second-order consolidation and capex/M&A cycles play out over 6–18 months.

Among the named names, differentiate operational leverage from multiple expansion. High fixed-cost, location-based operators (gaming) will amplify any consumer-takeback but are also most exposed to state regulatory shifts and local demand volatility; consumer-branded footwear benefits from faster marketing-to-sales payback as cost-of-capital falls but can be inventory-sensitive in the next two quarters; specialty chemicals/ingredients have both margin cyclicality and opportunistic M&A optionality that could create asymmetric upside if raw-materials stabilize; licensing-heavy franchises are durable but their re-rating depends on visible secular growth in content/device sell-through and new AI-driven use cases. Monitor cross-asset signals (consumer credit spreads, IG HY flows, and USD moves) as 1–3 month leading indicators for demand risk.

Tail risks are clear: a re-acceleration in services inflation, a Fed that delays cuts, or commodity/input shocks that erode gross margins would reverse momentum quickly. Catalysts to watch are monthly consumption/readings, Fed dot-plot language around the next 60–120 days, and company-level inventory/guide commentary in upcoming quarterlies. The consensus is underweight idiosyncratic execution and regulatory risk; therefore prefer structures that buy convex upside while capping downside (options or buy-writes) rather than unhedged outright long exposure across the board.

Key Decisions for Investors

• ALTO — Core long (5% portfolio): buy shares or 12–18 month LEAP ITM calls (50–60% delta) sized to 5% of book; horizon 12–18 months. R/R: target 30–50% upside if margins recover/M&A occurs; cut to half size on 20% loss, exit on 50% gain. Rationale: high operating leverage + takeover optionality; hedge with a 12–18 month 25–30% OTM put if funding allows.
• CROX — Momentum long (3% portfolio): buy shares or buy-write to reduce carry; horizon 6–12 months. R/R: target 20–35% upside from re-accelerating sell-through; use a 20% trailing stop or sell-to-open 1–2 month OTM calls to finance position. Rationale: marketing ROI and lower rates should compress DSO and improve returns; watch inventory cadence in quarterly release.
• ACEL — Tactical long with convexity (2–3% portfolio): buy 3–6 month calls (0.4–0.6 delta) or small equity position with strict 20% stop. Horizon 3–9 months. R/R: 40–60% upside if consumer bins re-open and consolidation picks up; downside is regulatory or localized demand shock—keep position small and time entries after municipal/state regulatory headlines clear.
• DLB — Selective buy-write (3% portfolio): establish small core equity stake and sell 3–6 month covered calls to fund carry, target 12–24 month horizon. R/R: modest 15–25% upside via re-rating plus premium; downside protected by premium but not immune to device sell-through weakness. Rationale: durable licensing with optional AI/UGC upside — monetize near-term uncertainty while retaining long-duration exposure.